Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and ...

Each inducement award is subject to the terms of the RxSight, Inc. 2026 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to these employees to ...

Idefirix ® was generally well tolerated with a safety profile consistent with previous clinical trial experience SERB acquired the European and MENA rights to Idefirix ® in transplantation in July ...

INDICATION XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response ...

Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet ...